A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity by Ng, Wai Tong et al.
Title
A multicenter, phase 3, randomized trial of concurrent
chemoradiotherapy plus adjuvant chemotherapy versus
radiotherapy alone in patients with regionally advanced
nasopharyngeal carcinoma: 10-year outcomes for efficacy and
toxicity
Author(s)
Lee, Anne W.M.; Tung, Stewart Y.; Ng, Wai Tong; Lee, Victor;
Ngan, Roger K.C.; Choi, Horace C.W.; Chan, Lucy L.K.; Siu,
Lillian L.; Ng, Alice W.Y.; Leung, To Wai; Yiu, Harry H.Y.;
O'Sullivan, Brian; Chappell, Rick
Citation Cancer, 2017, v. 123, n. 21, p. 4147-4157
Issued Date 2017
URL http://hdl.handle.net/10722/251703
Rights
This is the peer reviewed version of the following article: Cancer,
2017, v. 123, n. 21, p. 4147-4157, which has been published in
final form at https://doi.org/10.1002/cncr.30850. This article may
be used for non-commercial purposes in accordance with Wiley
Terms and Conditions for Self-Archiving; This work is licensed
under a Creative Commons Attribution-NonCommercial-
NoDerivatives 4.0 International License
  1 
A multicentre, phase 3, randomized trial on concurrent chemoradiotherapy 
plus adjuvant chemotherapy versus radiotherapy alone in patients with 
regionally advanced nasopharyngeal carcinoma: 10-year outcome on 
efficacy and toxicity 
 
Anne W.M. Lee MD
1
, Stewart Y. Tung FRCR
2
, W.T. Ng MD
3
, Victor Lee MD
1
, Roger K.C. 
Ngan FRCR
4
, Horace C.W. Choi PhD
1
, Lucy L.K. Chan BSc
3
, Lillian L. Siu MD
5
, Alice W.Y. 
Ng FRCR
2
, T.W. Leung MD
6
, Harry H.Y. Yiu FRCR
4
, Brian O’Sullivan MD5, and Rick 
Chappell PhD
7
. 
 
1
 Departments of Clinical Oncology, the University of Hong Kong and the University of Hong 
Kong-Shenzhen Hospital;  
2
 Tuen Mun Hospital, Hong Kong;  
3
 Pamela Youde Nethersole Eastern Hospital, Hong Kong 
4
 Queen Elizabeth Hospital, Hong Kong 
5
 Ontario Cancer Institute, Princess Margaret Cancer Centre, Toronto, Canada 
6
 Queen Mary Hospital, Hong Kong 
7
 Department of Biostatistics, University of Wisconsin Medical School, Madison, USA 
 
Corresponding author: Anne W.M. Lee, Department of Clinical Oncology, The University 
of Hong Kong and the University of Hong Kong-Shenzhen Hospital, 1/F, Professorial Block, 
Queen Mary Hospital, Pokfulam Road, Hong Kong  
Email: awmlee@hku.hk 
Tel: 852-22555050 
 2 
 
Running title: 10-year outcome of CRT for advanced NPC 
 
Total number of text pages (including title page, references, and figure legends) = 20; tables = 
3; and figures = 3 
 
AUTHOR CONTRIBUTIONS 
Conceptualization: Anne W.M. Lee, Stewart Y. Tung, W.T. Ng and Roger K.C. Ngan.  
Methodology: Anne W.M. Lee, Stewart Y. Tung, W.T. Ng, Roger K.C. Ngan, Lillian L. 
Siu, Brian O’Sullivan and Rick Chappell. Formal analysis: Horace C.W. Choi, Lucy L.K. 
Chan and Rick Chappell. Investigation: Anne W.M. Lee, Stewart Y. Tung, W.T. Ng, 
Victor Lee, Roger K.C. Ngan, Alice W.Y. Ng, T.W. Leung and Harry H.Y. Yiu. 
Resources: Anne W.M. Lee, Stewart Y. Tung, W.T. Ng, Victor Lee, Roger K.C. Ngan, 
Alice W.Y. Ng, T.W. Leung and Harry H.Y. Yiu. Data curation: Horace C.W. Choi and 
Lucy L.K. Chan. Writing – original draft: Anne W.M. Lee and W.T. Ng. Writing – review 
and editing: All authors. Visualization: Horace C.W. Choi and Lucy L.K. Chan. 
Supervision: Anne W.M. Lee, Stewart Y. Tung, W.T. Ng and Roger K.C. Ngan. Project 
administration: Anne W.M. Lee, Stewart Y. Tung, W.T. Ng and Roger K.C. Ngan. 
Funding acquisition: Anne W.M. Lee, Stewart Y. Tung and Roger K.C. Ngan. 
 
FUNDING SUPPORT 
This trial was supported by grants from three non-government organizations: Hong Kong 
Cancer Fund, Ho Hung Chiu Medical Foundation Limited, and the Hong Kong Anti-Cancer 
Society. 
  3 
 
CONFLICT OF INTEREST DISCLOSURES  
None of the authors have any potential conflict of interest. 
 
PRECIS 
Compared with radiotherapy alone, concurrent chemotherapy and adjuvant chemotherapy 
could significantly improve overall survival for patients with regional advanced 
nasopharyngeal carcinoma without excessive increase in late toxicities.  
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ABSTRACT 
Background 
Concurrent-adjuvant chemoradiotherapy (CRT) became a recommended treatment for 
locoregionally advanced nasopharyngeal carcinoma (NPC) since the first report of significant 
survival benefit by the Intergroup-0099 Study. However, data on late toxicities are lacking. 
Previous reports from the current NPC-9901 Trial raised concerns about failure to improve 
overall survival (OS) due to inadequate impact on distant control, and increase in 
toxicities/non-cancer deaths. Validation of the long-term therapeutic ratio is needed.  
Methods 
In this phase 3, randomized trial, patients with non-keratinizing NPC staged T1–4N2–3M0 
were randomly assigned to radiotherapy (RT) alone (176 patients) or to CRT (172 patients) 
using concurrent cisplatin followed by adjuvant cisplatin plus fluorouracil.  
Results 
The early findings of significant improvement in tumor control were maintained: the CRT 
group achieved significantly higher 10-year overall failure-free rate (62% vs 50%, P=0.01) and 
progression-free survival (56% vs 42%, P=0.006) due to superior locoregional-control (87% 
vs 74%, P=0.003), whilst the impact on distant-control remained insignificant (68% vs 65%, 
P=0.24). The initial differences in toxicities diminished with longer follow up: late toxicity rate 
(52% vs 47% at 10 years, P=0.20), deaths due to treatment-toxicity (4.1% vs 2.8%) or 
incidental/unknown cause (15.1% vs 13.1%). The OS rate in the CRT group reached 
statistical superiority at 10-year (62% vs 49%, P=0.047).  
Conclusions 
Long-term results confirmed that CRT could significantly improve OS without excessive late 
toxicities for patients with regionally advanced NPC. However, more potent therapy is needed 
for improving distant control, especially for patients with stage IVA–B disease. 
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INTRODUCTION 
Radiotherapy (RT) has been the primary treatment modality for nasopharyngeal 
carcinoma (NPC) since the advent of megavoltage technology. Addition of chemotherapy to 
RT is an important strategy for improving tumour control of locoregionally advanced NPC 
because this has potential for both enhancing the local effect of RT and eradicating micro-
metastases. Although NPC is relatively chemo-sensitive, survival benefit was not demonstrated 
until the Intergroup-0099 Study using concurrent-adjuvant chemoradiotherapy (CRT).
1
 
Preliminary results on patients with Stage II–IVB disease (using the staging criteria of the 
TNM system 5
th
 edition) showed very impressive improvement in all endpoints, with overall 
survival (OS) of 78% vs 47% at 3 years. However, when the results were first reported in the 
late 1990s, there were concerns about the exact magnitude of benefit because the outcomes 
for their RT group were substantially worse than those by other studies in the same period. 
Furthermore, there were no data on late toxicities.  
This led to confirmatory trials in Asia where NPC is most prevalent.
2-8
 Both Wee et 
al.
2,3 and Chen et al.
4,5
 showed that concurrent-adjuvant CRT could significantly improve both 
the event-free survival (EFS) and OS for patients with Stage III–IVB disease. The NPC-9901 
Trial
6,7
 initiated by Hong Kong Nasopharyngeal Cancer Study Group differed from the other 
trials as we focused on patients with T1–4N2–3 disease (the group with highest risk of distant 
failure). While our Trial concurred that the Intergroup-0099 regimen could significantly 
improve EFS, our 3-year
6
 and 5-year
7
 results did not show significant gain in OS, due partly to 
insignificant improvement in distant control and partly to increased deaths due to treatment 
toxicities and incidental causes. 
 We continued to follow-up the surviving patients to assess the late toxicities and 
pattern of failure. The current study provided a unique opportunity for evaluating the ultimate 
impact on the therapeutic ratio by the addition of concurrent-adjuvant CRT for NPC and to 
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identify learning points for future studies. 
 
PATIENTS AND METHODS 
Study design and patients 
 This multicentre, phase 3, randomized-controlled trial was participated by four centres 
from Hong Kong and one centre from Canada. As shown in previous reports,
6,7
 the key 
eligibility criteria included histologically confirmed non-keratinizing (differentiated or 
undifferentiated) carcinoma of the nasopharynx as classified by the World Health Organization 
(WHO) system, and T1–4N2–3M0 disease by TNM Classification 5th edition.   
 All participants provided written informed consent. The protocol was approved by the 
institutional ethics committees of the individual participating centre. The trial was conducted 
in accordance with the Declaration of Helsinki, and was monitored by an independent Data 
Monitoring Committee.  
 Eligible patients were stratified by participating centre, T-category (T1–2 vs T3–4) and 
N-category (N2 vs N3). They were randomly assigned using a blocked randomisation scheme 
in a 1:1 ratio, to receive either RT alone (the RT group) or in combination with concurrent-
adjuvant chemotherapy (the CRT group). Randomisation was generated by the consulting 
statistician in sealed envelopes labelled by stratum, which were unsealed only after patient 
registration. Treatment allocation was not masked, but the statisticians were blinded. 
 
Assessment and Treatment 
Details of the assessment, treatment and statistical methods have been described in 
previous reports.
6,7
 Patients in both treatment groups were irradiated with megavoltage 
photons using the same RT technique and dose in line with the treatment policy of each 
individual centre. Those assigned to the CRT group were given additional chemotherapy using 
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the Intergroup-0099 regimen:
1
 Cisplatin (100 mg/m
2
) was given intravenously every 3 weeks 
for three cycles starting with commencement of RT, followed subsequently by a combination 
of cisplatin (80 mg/m
2
) plus fluorouracil (1000 mg/m
2
/day by 96-hour infusion) every 4 weeks 
for three cycles.  
 The first assessment of tumour response was performed 6 to 16 weeks after 
completion of RT. For statistical purposes, persistent primary or nodal disease at 16 weeks 
after completion of RT was defined as locoregional failure. Treatment of residual disease and 
tumour relapse (if detected) was given in line with the policy of the individual centre. 
Radiotherapy-related late toxicities were graded according to the Late Radiation Morbidity 
Scoring Criteria of the Radiation Therapy Oncology Group (RTOG).  
 
Statistical Methods 
 All events were measured from the date of random assignment. The primary endpoints 
included overall failure-free rate (FFR: time to first failure at any site) and progression-free 
survival (PFS: time to first failure or death from any cause). Secondary endpoints for 
treatment efficacy included OS, locoregional-FFR (LR-FFR) and distant-FFR (D-FFR). 
Secondary endpoints for safety included major toxicities (except xerostomia and dental caries) 
of grade 3 or greater; the current paper focused on late toxicities. For patients who had re-
irradiation for treatment of locoregional relapses, events were censored at commencement of 
re-irradiation for assessing toxicities incurred solely by the primary treatment.  
 All analyses were performed on an intention-to-treat basis; statistical tests comparing 
treatment groups were two-sided, and P values less than 0.05 were considered to indicate 
statistical significance. Further to calculation of the hazard ratios (HR) by the Cox regression 
model, the assumptions of proportional hazards were confirmed basing on Schoenfeld 
residuals.  
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 This trial was registered with HAREC Clinical Trial Registry by the Hong Kong 
Hospital Authority (ID number: HARECCTR0500023) in accordance to the WHO 
International Clinical Trial Registry Platform (ICTRP) requirements. 
 
RESULTS 
 From March 1999 to January 2004, in compliance with the targeted accrual size of 
340, 348 eligible patients were randomly assigned (Figure 1), and only 4% were lost to follow-
up. All survivors had a minimum follow-up of 10 years, the median duration for the whole 
series was 10.7 years (range = 0.2–16.8 years).  
 The two treatment groups were well balanced in all patient characteristics, tumour 
factors and RT parameters (Table A1).  Four patients had major protocol violations (Figure 
1): 2 patients (1.2%) in the CRT group did not receive chemotherapy and 2 patients (1.1%) in 
the RT groups received chemotherapy. The compliance to chemotherapy the CRT group has 
been described in previous report.
6
 
 
Efficacy 
 Details of outcome comparisons are shown in Table 1 and Figure 2. Altogether, 150 
patients failed (at one or more sites), and 183 died (of any cause). When compared with the 
RT alone group, the CRT group achieved significantly higher overall-FFR (62% vs 50%), PFS 
(56% vs 42%), and cancer-specific survival (72% vs 58%) at 10-year. The improvement was 
strongly significant for locoregional-FFR (87% vs 74%), but insignificant for distant-FFR 
(68% vs 65%). 
 Among the patients with relapse, the majority [44/63 (70%) in the CRT group and 
66/87 (76%) in the RT group] were given further treatment. Besides aggressive locoregional 
treatment, chemotherapy was used in 33 patients in the CRT group and in 53 patients in the 
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RT group. The successful salvage rates (alive without disease at last assessment) were 9% in 
both groups.  
 The OS rate of the CRT group became superior to the RT group with longer follow-
up (62% vs 49% at 10-year, P=0.010). Analyses on the incidence of deaths due to different 
causes (Table A2) showed that the CRT group had significant reduction in deaths due to 
disease progression (27.3% vs 42.6%, P=0.004), without significant increase in deaths directly 
attributable to chemotherapy/RT toxicity (4.1% vs 2.8%, P=0.74) or incidental/unknown 
causes (15.1% vs 13.1%, P=0.69). Further analyses on the pattern at different period showed 
that excess in non-cancer deaths in the CRT group was 5.9% for patients with observation ≤5 
years, but no increase for those with longer follow-up. On the other hand, deaths due to 
treatment toxicity increased in the RT group from 0%, 1.8% to 3.6% for patients with 
observation ≤5 years, >5–≤10 years, and >10 years, respectively.  
 Subgroup analyses (Table 1) showed a favourable trend in all endpoints (except distant 
failure) by adding chemotherapy for both Stage III (n=206) and Stage IVA–B (n=142), but 
the magnitude of hazard reduction was generally greater for Stage III. The 10-year OS in the 
CRT group was 74% for Stage III, but only 45% for Stage IVA–B (P=0.031, Figure 3). 
 Multivariable analyses (Table 2) based on the intention-to-treat principle showed that 
addition of chemotherapy is an independent factor for improving all endpoints except distant-
FFR.  
 Further analyses of outcome based on actual treatment showed that patients who had 
received 2 or more cycles in the concurrent phase (n=164) achieved significantly better LR-
FFR (P=0.001), but the impact in D-FFR was insignificant (P=0.15). Patients who had 
received 2 or more cycles in both the concurrent and the adjuvant phases (n=140) achieved 
significant improvement in both 10-year LR-FFR (87.9% vs 75.0%, P=0.003) and D-FFR 
(73.0% vs 61.8%, P<0.001).   
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Safety 
 Altogether, there were 132 incidences of late toxicity grade 3 or above (Table 3). The 
mean latency from commencement of RT to the manifestation of late toxicity was 4.2 years in 
the CRT group versus 4.7 years in the RT-alone group (P=0.40). The overall actuarial rate of 
grade 3 late toxicity was higher in the CRT group during the first 3 years. However, the 
difference gradually diminished and became insignificant: 52.3% vs 46.8% at 10 years 
(absolute difference 5.5%), P=0.20; hazard ratio (HR) 1.25 (95% confidence level [CI] 0.89–
1.76) (Figure 2).  
 None of the damage of different normal structures showed statistically significant 
excess in the CRT group (Table 3). Multivariable analysis (Table 2) showed that the addition 
of chemotherapy did not incur significant increase in major late toxicity (HR 1.22, 95% CI 
0.86–1.72). Eleven patients developed second malignancy within the irradiated areas, it is not 
possible to tell whether they are de-novo or radiation-induced. However, basing on the 
location and latency, we regard them as RT toxicity to avoid underestimating the problem.
 There was no statistical difference in mortality rate due to RT toxicity between the 
CRT and the RT groups (3.5% vs 2.8%). Altogether 11 patients died of RT-induced late 
toxicities – including eight due to second malignancy within RT portal, and the other three due 
to temporal lobe necrosis, skull base necrosis, and aspiration pneumonia related to last four 
cranial nerve palsies, respectively.  
 
DISCUSSION 
Among the four randomized trials evaluating the addition of concurrent cisplatin plus 
adjuvant cisplatin-fluorouracil to conventional-fractionated RT,
1-9
 our NPC-9901 Trial is the 
trial with the largest sample size and the only trial that focused on patients with N2–3 disease 
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(the group with highest metastatic risk); the current update is the first report with detailed 10-
year outcome for both efficacy and late toxicities to evaluate the ultimate therapeutic ratio. 
Similar to the trials by Wee et al.
2,3
 and Chen et al.,
4,5
 the current trial is confined to patients 
with non-keratinizing carcinoma, the applicability to keratinizing carcinoma is uncertain. 
Another point to note is the RT technique used:  only 51% of patients in our series were 
irradiated with 3-dimensional conformal technique throughout, the magnitude of benefit in the 
modern era of intensity-modulated RT has yet to be studied. 
All four trials consistently confirmed that concurrent-adjuvant CRT could significantly 
improve PFS. Evaluation at 5 years showed an absolute gain of 29% by the Intergroup-0099 
Study,
9
 while the three confirmatory trials showed a fairly consistent absolute gain of 9–
13%,
3,5,7
 with reduction in hazard of failure or death at 28–35%. The current update confirmed 
that this significant improvement was maintained at 10 years (14% absolute gain, and 32% 
hazard reduction). 
 The impact by concurrent-adjuvant CRT on the pattern of failure is less clear; the 
variation might be explained at least partly by the differences in the proportion of advanced T- 
and N-categories among the trials. Both the preliminary reports by Intergroup-0099 Study
1
 
and Chen et al.
4
 showed significant improvement in both locoregional-FFR and distant-FFR. 
However, both endpoints became insignificant in the subsequent 5-year report by Chen et al.
5
 
For our NPC-9901 Trial (42% with T3–4, 100% with N2–3 disease), assessments at all time-
points showed significant improvement in locoregional-FFR; the current update confirmed a 
significant 13% absolute gain at 10 years with CRT (87% vs 74%). However, our trial raised 
the concern that the impact on distant-FFR was statistically insignificant throughout all time-
points for this cohort of patients: with an absolute gain of only 3% (68% vs 65% at 10 years).  
While the other three trials showed significant improvement in OS,
1-5,9 
previous reports 
from our NPC-9901 Trial showed contrary results: the OS in the CRT group was almost 
  13 
identical to the RT alone group at 3-year,
6
 and only diverged to a 4% gain at 5-year.
7
 
Interestingly, this divergence steadily widened to reach statistical significance with hazard 
reduction of 26% and an absolute gain of 13% at 10 years (Figure 2: 62% vs 49%),  
  
 This trend in OS was not due to the pattern of failures, but rather the pattern of deaths 
from treatment toxicities and incidental/unknown causes (Table A2). Our early reports 
attributed the increase in deaths to incidental/unknown causes,
6,7
 but these diminished with 
longer follow-up and became insignificant in the current analyses (19% vs 16%).  At 3 years 
CRT incurred a significant 31% increase in acute toxicities and 15% increase in late toxicities 
of grade 3 or above when compared with RT alone, but the difference in actuarial late toxicity 
rate gradually narrowed to 6% at 5- and 10-year (Figure 2).  In this series the deaths due to 
treatment toxicity steadily increased in the RT group from 0% for survivors with ≤5 years 
follow-up to 3.6% for those >10 years.  It appeared that the latency to radiotherapy-induced 
toxicities was shorter in the CRT group when compared with the RT groups (4.7 vs 4.2 
years), though the difference was not statistically significant (P=0.40).  
 Our current study also cautioned the predicting power of short term PFS on long term 
survival endpoints. The study by Rotolo et al. on NPC showed that the 3-year PFS could 
predict the 5-year OS 
10
. In our series, while there was no difference in PFS between the RT 
and CRT groups at 3-year, the difference became significant at 5-year and was maintained at 
10-year. This is because, in short term, the benefit of improved tumor control by CRT was 
offset by the death from toxicities or incidental causes, and PFS combines both the treatment 
failure and death by any cause. It is only when we look at just the treatment failure pattern that 
the overall-FFR at 3-year could really predict the final tumor control rate as indicated by the 
FFR at 5-year and 10-year. The pattern of failures at locoregional and distant sites at 3-year 
was also maintained at 5-year and 10-year. 
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 Similarly, the difference in OS between the RT and CRT groups was statistically 
insignificant at both 3-year 
6
 and 5-year 
7
, but this became significant at 10-year because of the 
slowly increasing rate of deaths due to late toxicities in the RT group. Hence, it is important to 
note that for disease with notoriously high risk of late toxicities, long term follow-up is needed 
to fully assess the ultimate therapeutic ratio. 
 Hence, it is reassuring that all four randomized trials consistently confirmed that 
concurrent-adjuvant chemotherapy could significantly improve both PFS and OS. More 
importantly, the current update with a median observation period of 10.7 years showed that 
this treatment was safe: with no significant increase in late toxicity or non-cancer deaths. 
Study by the MAC-NPC Collaborative Group,
11
 with a median follow-up of 7.7 years, 
similarly showed that addition of concurrent-adjuvant chemotherapy (total of 1267 patients) 
could significantly reduce the hazard of all deaths by 35% [HR 0.65 (0.56–0.76)], without 
significant increase in non-cancer deaths (HR 1.19 (0.77–1.85)]. This favorable long-term 
therapeutic ratio for NPC is contrary to the RTOG 91-11 Trial for laryngeal cancer,
12
 which 
showed loss of survival gain by concurrent cisplatin (OS 28% vs 32% at 10 years) due to 
significant increase in non-cancer deaths (31% vs 17%).  
 One unresolved uncertainty is the exact magnitude of contribution by the adjuvant 
phase. Results from the randomized trial by Chen et al. comparing concurrent-adjuvant 
chemotherapy versus concurrent chemotherapy showed that the concurrent-adjuvant group 
did not achieve significant increase in estimated 5-year FFR [HR 0.88 (0.64–1.22)].13 
However, it should be cautioned that the impact on outcome for NPC could take a prolonged 
period to manifest (as shown by our study), long-term follow-up is needed for definitive 
conclusion.  
 The analyses by the MAC-NPC Collaborative Group favored additional 
chemotherapy.
11,14
 The comparisons on concurrent chemotherapy were more heterogeneous: 
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review of individual trials showed that only the trial using concurrent cisplatin for patients 
largely with stage II disease treated by 2-dimensional RT achieved significant benefit in both 
PFS and OS.
15
 Ranking of different treatment strategies by network analyses showed that the 
concurrent-adjuvant chemotherapy group achieved the highest benefit on OS and PFS when 
compared with RT alone: the P-Scores were 96% and 94% respectively, while the 
corresponding P-Scores by concurrent chemotherapy group was 70% and 52% (P-score is the 
statistical score to indicate the extent of certainty that a treatment is better than other 
competing treatments, higher P-Score means greater probability of being the best).
14
 The 
concurrent-adjuvant group achieved significantly better PFS than the concurrent group [HR 
0.81 (0.66–0.98)].  
 Although the current concurrent-adjuvant chemotherapy is consistently superior to RT 
alone, our trial showed that further improvement in efficacy for distant control is needed, 
especially for patients with Stage IVA–B disease. A major reason for inadequate impact on 
distant control is the poor tolerance in the adjuvant phase. Analyses of outcome based on 
actual treatment showed that patients who had received 2 or more cycles in both the 
concurrent and the adjuvant phases achieved significant improvement not only in LR-FFR but 
also in D-FFR.   
 One potential strategy for improvement is to change the time sequence to induction-
concurrent as early administration of potent chemotherapy combination at full dose could be 
more effective for eradication of micro-metastases.
16
 Indeed, the network analyses by the 
MAC-NPC Collaborative Group
14
 showed that the induction-concurrent group achieved the 
highest benefit on D-FFR as compared with concurrent-adjuvant and concurrent-alone groups: 
the P-scores were 95%, 72% and 48% respectively.    
 Early trials evaluating induction-concurrent versus concurrent-alone chemotherapy 
showed conflicting outcome, but promising 3-years result were recently reported by Sun et al. 
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using induction cisplatin, fluorouracil, and docetaxel followed by concurrent cisplatin (80% vs 
72%, P=0.034),
17
 and Cao et al. using induction cisplatin and fluorouracil followed by 
concurrent cisplatin (82% vs 74%, P=0.028).
18
 The NPC-0501 Trial by The Hong Kong 
Nasopharyngeal Cancer Study Group was the only trial that aimed to evaluate induction-
concurrent versus concurrent-adjuvant chemotherapy: preliminary results showed that the 
group randomized to receive induction cisplatin-capecitabine followed by cisplatin in 
concurrence with conventional-fractionated RT achieved better PFS than the concurrent-
adjuvant group (81% vs 75% at 3-years, P=0.045).
19
 Longer follow-up of these trials are 
needed for confirmation, especially as there is concern that the induction chemotherapy may 
affect the tolerability of chemotherapy at the concurrent phase. 
 Another key focus for future trial is personalized refinement of treatment strategy. An 
on-going NRG trial (NCT02135042) attempts to use post-RT EBV-DNA level for tailoring 
adjuvant chemotherapy. Furthermore, we should explore the possibility of identifying patients 
who could be safely treated with RT alone. Current guidelines recommend CRT for all Stage 
II–IVB patients, but even for the current cohort with suboptimal RT technique by modern 
standard, 50% of Stage III and 29% Stage IVA–B treated by RT alone were progression-free 
at 10-year. Further clinical and translational studies are needed to identify good-risk patients 
who can be spared of unnecessary chemotherapy. 
 
Conclusion 
 Long-term results of the NPC-9901 Trial confirm that adding concurrent cisplatin plus 
adjuvant cisplatin-fluorouracil to conventional-fractionated RT could significantly improve 
both PFS and OS at 10 years, without significant increase in late treatment toxicities and non-
cancer deaths. However, exploration for more potent regimen for distant control is needed, 
especially for patients with Stage IVA–B disease. Further clinical and translational studies are 
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also needed to work towards personalised medicine and spare good-risk patients of over-
treatment.
 18 
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Figure Legends 
Figure 1. CONSORT flow diagram showing design, enrolment and outcomes of this study 
(NPC-9901 Trial). Patients with T1–4N2–3M0 nasopharyngeal carcinoma were randomly 
assigned to radiotherapy either alone or with addition of concurrent-adjuvant chemotherapy. 
Figure 2. Comparisons of the chemoradiotherapy (CRT) group versus the radiotherapy-alone 
(RT) group in terms of (a) overall failure-free rates, (b) progression-free survival, (c) overall 
survival, (d) locoregional failure-free rate, (e) distant failure-free rate, and (f) major late 
toxicity grade 3 or above. The vertical solid lines showed the 95% CI of the Kaplan-Meier 
estimates at 5, 10 and 15 years. 
Figure 3. Subgroup analyses – Comparisons on efficacy of the chemoradiotherapy (CRT) 
group versus the radiotherapy-alone (RT) group in the Stage III and Stage IVA–B Subgroups 
in terms of (i) locoregional failure-free rate, (ii) distant failure-free rate, and (iii) overall 
survival. 
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Figure 1. CONSORT flow diagram showing design, enrolment and outcomes of this study 
(NPC-9901 Trial). Patients with T1–4N2–3M0 nasopharyngeal carcinoma were randomly 
assigned to radiotherapy either alone or with addition of concurrent-adjuvant chemotherapy. 
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Figure 2. Comparisons of the chemoradiotherapy (CRT) group versus the radiotherapy-alone 
(RT) group in terms of (a) overall failure-free rates, (b) progression-free survival, (c) overall 
survival, (d) locoregional failure-free rate, (e) distant failure-free rate, and (f) major late 
toxicity grade 3 or above. The vertical solid lines showed the 95% CI of the Kaplan-Meier 
estimates at 5, 10 and 15 years. 
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Figure 3. Subgroup analyses – Comparisons on efficacy of the chemoradiotherapy (CRT) 
group versus the radiotherapy-alone (RT) group in the Stage III and Stage IVA–B Subgroups 
in terms of (i) locoregional failure-free rate, (ii) distant failure-free rate, and (iii) overall 
survival. 
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Table 1: Comparison of efficacy outcome - Chemoradiotherapy group versus 
radiotherapy-alone group 
Endpoints Whole cohort Subgroup analysis 
Actuarial rate at 10 years 
HR of defining events (95% CI) 
T1–4N2–3 
(n=348) 
III 
(n=206) 
IVA–B 
(n=142) 
Overall failure-free rate 
 
62% vs 50% 
P=0.010 
0.66 (0.47–0.91)  
75% vs 59% 
P=0.008 
0.51 (0.31–0.85) 
44% vs 37% 
P=0.12 
0.71 (0.46–1.10)  
Progression-free survival  
 
56% vs 42% 
P=0.006 
0.68 (0.51–0.90) 
70% vs 50% 
P=0.004 
0.55 (0.36–0.83) 
38% vs 29% 
P=0.13 
0.74 (0.50–1.09)  
Overall survival 62% vs 49% 
P=0.047 
0.74 (0.56–0.997)  
74% vs 60% 
P=0.031 
0.62 (0.40–0.96)  
45% vs 31% 
P=0.28 
0.80 (0.54–1.20)  
Cancer-specific survival 72% vs 58% 
P=0.008 
0.61 (0.43–0.88) 
83% vs 68% 
P=0.009 
0.46 (0.26–0.84)  
56% vs 42% 
P=0.11 
0.68 (0.42–1.09)  
Locoregional failure-free rate 87% vs 74% 
P=0.003 
0.45 (0.26–0.77) 
90% vs 77% 
P=0.013 
0.39 (0.18–0.84)  
83% vs 69% 
P=0.06 
0.49 (0.23–1.04)  
Distant failure-free rate 68% vs 65% 
P=0.24 
0.80 (0.55–1.16) 
80% vs 74% 
P=0.17 
0.66 (0.37–1.19) 
52% vs 49%  
P=0.41 
0.82 (0.50–1.32)  
HR = hazard ratio; CI = confidence interval; P values were calculated by log-rank test  
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Table 2: Multivariable analysis on significance of treatment group (based on intention-
to-treat) and other potential covariates: Hazard ratio (95% Confidence Interval) 
Factor Locoregional 
failure 
Distant 
failure 
All 
failure 
Failure 
or death 
All death Cancer-
specific 
survival 
Late 
toxicity 
Treatment 
group: 
  CRT vs RT 
alone 
0.41 (0.23–
0.72) 
P=0.002 
0.71 
(0.48–
1.04) 
P=0.08 
0.58 
(0.42–
0.81) 
P=0.002 
0.61 
(0.46–
0.82) 
P=0.001 
0.68 
(0.50–
0.92) 
P=0.013 
0.56 
(0.39–
0.81) 
P=0.002 
1.22 
(0.86–
1.72) 
P=0.27 
Stage group: 
   IV vs III  
1.55 (0.91–
2.63) 
P=0.11 
2.39 
(1.61–
3.54) 
P<0.001 
2.18 
(1.56–
3.06) 
P<0.001 
1.91 
(1.43, 
2.55) 
P<0.001 
1.77 
(1.31–
2.40) 
P<0.001 
2.20 
(1.51–
3.20) 
P<0.001 
1.52 
(1.03–
2.23) 
P=0.034 
Lactate 
dehydrogenase
: 
   per 10 iu/L 
increase 
1.004 
(0.973–
1.036) 
P=0.78 
1.019 
(0.9997–
1.038) 
P=0.54 
1.019 
(1.002–
1.036) 
P=0.031 
1.023 
(1.008–
1.038) 
P=0.002 
1.034 
(1.018–
1.049) 
P<0.001 
1.030 
(1.012–
1.049) 
P=0.001 
1.021 
(1.001–
1.042) 
P=0.042 
Age:  
   per year 
increase 
1.02 (0.99–
1.04) 
P=0.23 
1.01 
(0.99–
1.03) 
P=0.19 
1.01 
(0.996–
1.03) 
P=0.12 
1.02 
(1.01–
1.04) 
P=0.002 
1.03 
(1.01–
1.05) 
P<0.001 
1.03 
(1.01–
1.05) 
P=0.006 
1.02 
(1.01–
1.04) 
P=0.013 
Gender:  
female vs male 
0.40 (0.18–
0.88) 
P=0.023 
0.72 
(0.43–
1.19) 
P=0.20 
0.59 
(0.37–
0.92) 
P=0.021 
0.57 
(0.39–
0.84) 
P=0.005 
0.56 
(0.37–
0.85) 
P=0.007 
0.66 
(0.40–
1.08) 
P=0.10 
1.70 
(1.17–
2.48) 
P=0.005 
Radiotherapy 
technique: 
1.09 (0.48–
2.49) 
1.01 
(0.57–
1.18 
(0.72–
1.29 
(0.83–
1.57 
(0.98–
1.25 
(0.70–
1.30 
(0.66–
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  3D vs 
2D±boost 
P=0.84 1.79) 
P=0.98 
1.95) 
P=0.51 
2.01) 
P=0.25 
2.52) 
P=0.06 
2.22) 
P=0.45 
2.56) 
P=0.45 
Radiotherapy 
dose: 
   per Gy 
increase 
0.92 (0.90–
0.95) 
P<0.001 
0.94 
(0.91–
0.98) 
P<0.001 
0.94 
(0.91–
0.96) 
P<0.001 
0.94 
(0.92–
0.97) 
P<0.001 
0.95 
(0.92–
0.97) 
P<0.001 
0.96 
(0.92–
1.01) 
P=0.09 
1.06 
(0.94–
1.20) 
P=0.34 
*Statistically significant factors on univariable analyses: age, gender, stage group, lactate dehydrogenase, 
radiotherapy technique and total dose. 
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Table 3: Late Toxicities 
  Chemoradiotherapy (N = 172) Radiotherapy (N = 176)  
Toxicity grade, No. (%) 3 4 5 3 4 5 P value 
Neurological structures 11 (6.4) 1 (0.6) 2 (1.2) 15 (8.5) 0 (0) 0 (0) 0.32 
Temporal lobe necrosis 1 (0.6) 1 (0.6) 1 (0.6) 1 (0.6) 0 (0) 0 (0) 0.75 
Brainstem damage 0 (0) 0 (0) 0 (0) 1 (0.6) 0 (0) 0 (0) 1.00 
Brachial plexopathy 0 (0) 0 (0) 0 (0) 1 (0.6) 0 (0) 0 (0) 1.00 
Cranial Neuropathy
a
 7 (4.1) 0 (0) 1 (0.6) 13 (7.4) 0 (0) 0 (0) 0.25 
Peripheral neuropathy 4 (2.3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0.06 
Soft tissue and bone 13 (7.6) 6 (3.5) 4 (2.3) 18 (10.2) 5 (2.8) 5 (2.8) 0.85 
Bone necrosis 0 (0) 1 (0.6) 0 (0) 0 (0) 1 (0.6) 1 (0.6) 1.00 
Soft tissue damage
b
 12 (7.0) 4 (2.3) 0 (0) 17 (9.7) 1 (0.6) 0 (0) 0.27 
Dysphagia 2 (1.2) 0 (0) 0 (0) 4 (2.3) 0 (0) 0 (0) 0.68 
Vascular (bleeding) 2 (1.2) 2 (1.2) 0 (0) 1 (0.6) 1 (0.6) 0 (0) 0.57 
Radiation-induced malignancy
c
  0 (0) 1 (0.6) 4 (2.3) 0 (0) 2 (1.1) 4 (2.3) 1.00 
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Ear (hearing impairment / otitis) 39 (22.7) 8 (4.7) 0 (0) 32 (18.2) 4 (2.3) 0 (0) 0.26 
Eye 1 (0.6) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0.49 
Endocrine dysfunction 17 (9.9) 0 (0) 0 (0) 13 (7.4) 0 (0) 0 (0) 0.45 
Late toxicity at any structure (max 
grade) 
54 (31.4) 12 (7.0) 6 (3.5) 46 (26.1) 9 (5.1) 5 (2.8) 0.52 
P values were calculated across toxicity grades (grades 0-2, 3, 4 and 5) by χ2 test (or Fisher’s exact test when appropriate). 
a 
Patients with toxicities in cranial neuropathies: XII (19),  XII + VI (1) and VII (1). Optic nerve damage was not reported in this study; 
b 
Soft 
tissue damage included head and neck tissue necrosis, fibrosis and trismus; 
c 
Patients with radiation-induced malignancy: squamous cell carcinoma 
of the oral cavity (5), soft tissue sarcoma over the irradiated area (5), and thyroid cancer (1). 
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Additional Tables (Online only) 
Table A1. Baseline characteristics and primary radiotherapy 
Table A2. Incidence of deaths due to different causes at different time-point  
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Table A1. Baseline characteristics and primary radiotherapy 
 
Chemoradiotherapy 
(n=172) 
Radiotherapy 
(n=176) 
P value 
Patient Characteristics    
Age, years 
   Mean ± SD 
 
46 + 10 
 
47 + 10 
 
0.42 
Gender, No. (%) 
   Male 
 
124 (72) 
 
139 (79) 
 
0.14 
   Female 48 (28) 37 (21)  
Performance status, No. (%) 
   0  
 
148 (86) 
 
151 (86) 
 
0.37 
   1 24 (14) 23 (13)  
   2 0 2 (1)  
T-category, No. (%) 
   T1-2 
 
100 (58) 
 
103 (59) 
 
0.94 
   T3-4 72 (42) 73 (41)  
N-category, No. (%) 
   N2 
 
117 (68) 
 
119 (68) 
 
0.94 
   N3 55 (32) 57 (32)  
Stage group, No. (%) 
   III  
 
98 (57) 
 
108 (61) 
 
0.41 
   IVA-B 74 (43) 68 (39)  
Lactate dehydrogenase, IU/L 
   Mean ± SD  
 
282 ±152 
 
271 ± 128 
 
0.45 
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Radiotherapy    
Technique, No. (%) 
   2-dimensional throughout 
 
69 (40) 
 
73 (41) 
0.89 
 
   2 dimensional + conformal 13 (8) 15 (9)  
   Conformal throughout 90 (52) 88 (50)  
Total dose, Gy   
  Mean ± SD  
 
67.8 ± 7.4 
 
68.5 ± 2.7 
 
0.28 
Overall treatment time, days 
  Mean ± SD  
 
46 ± 6 
 
46 ± 3 
 
0.59 
Additional boost, No. (%) 
  Nasopharynx / parapharyngeal 
space 
 
59 (34) 
 
72 (41) 
 
0.20 
SD = standard deviation; IU = international units; Gy = gray (radiation units). 
 P values were calculated by two-sided t-test or χ2 test. 
Performance status: 0 = fully active, 1 = ambulatory but restricted by physically strenuous 
activity, 2 = ambulatory >50% of waking hours, but unable to work 
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Table A2. Incidence of deaths due to different causes at different time-point 
Cause of deaths Pattern at different time-points 
 Overall ≤5 years >5 to ≤10 years >10 years 
 CRT 
(n=172) 
RT 
(n=176) 
CRT 
(n=172) 
RT 
(n=176) 
CRT 
(n=115) 
RT 
(n=111) 
CRT 
(n=101) 
RT 
(n=83) 
Cancer 47 (27.3%) 75 (42.6%) 39 (22.7%) 59 (33.5%) 6 (5.2%) 13 (11.7%) 2 (2.0%) 3 (3.6%) 
Toxicity of chemotherapy / 
radiotherapy 
7 (4.1%) 5 (2.8%) 3 (1.7%) 0 (0.0%) 1 (0.9%) 2 (1.8%) 3 (3.0%) 3 (3.6%) 
Incidental / unknown cause 26 (15.1%) 23 (13.1%) 11 (6.4%) 4 (2.3%) 5 (4.3%) 11 (9.9%) 10 (9.9%) 8 (9.6%) 
 
 
 
